Abiopharma

🔍 Ramaswamy Vivek (Executive)

Company: Roivant Sciences Ltd. (ROIV)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Acquired 1,869,691 shares of Common Shares at $12.68 per share (Direct)
  Date: 2025-12-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,523,447.00 | transaction_form_type: 4
• Sold 774,142 shares of Common Shares at $21.64 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 34,749,305.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,095,550 shares of Common Shares at $21.64 per share (Direct)
  Date: 2025-12-11 | Code: J | equity_swap_involved: 0 | shares_owned_after: 33,653,755.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 4,672,724 shares of Common Shares at $12.68 per share (Direct)
  Date: 2025-12-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 38,326,479.00 | transaction_form_type: 4
• Sold 1,975,858 shares of Common Shares at $21.96 per share (Direct)
  Date: 2025-12-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 36,350,621.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 2,696,866 shares of Common Shares at $21.96 per share (Direct)
  Date: 2025-12-12 | Code: J | equity_swap_involved: 0 | shares_owned_after: 33,653,755.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Acquired 832,453 shares of Common Shares at $12.68 per share (Direct)
  Date: 2025-12-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,486,208.00 | transaction_form_type: 4
• Sold 353,745 shares of Common Shares at $22.05 per share (Direct)
  Date: 2025-12-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 34,132,463.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 478,708 shares of Common Shares at $22.05 per share (Direct)
  Date: 2025-12-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 33,653,755.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Holds 0 shares of Common Shares (Direct)
  Date: 2025-12-11 | Code: H | nature_of_ownership: Spousal | shares_owned_after: 13,357,857.00 | Footnotes: F5
• Sold 1,869,691 shares of Stock Option (Right to Buy) at $12.68 per share (Derivative)
  Date: 2025-12-11 | Code: M | Expires: 2026-03-31 | equity_swap_involved: 0 | shares_owned_after: 27,655,404.00 | transaction_form_type: 4 | Footnotes: F7, F6
• Sold 4,672,724 shares of Stock Option (Right to Buy) at $12.68 per share (Derivative)
  Date: 2025-12-12 | Code: M | Expires: 2026-03-31 | equity_swap_involved: 0 | shares_owned_after: 22,982,680.00 | transaction_form_type: 4 | Footnotes: F7, F6
• Sold 832,453 shares of Stock Option (Right to Buy) at $12.68 per share (Derivative)
  Date: 2025-12-15 | Code: M | Expires: 2026-03-31 | equity_swap_involved: 0 | shares_owned_after: 22,150,227.00 | transaction_form_type: 4 | Footnotes: F7, F6

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
• F2: Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive.
• F5: Represents the quantity of shares held indirectly only.
• F6: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
• F7: All options exercised by the reporting person would have expired in March 2026 if not exercised.